Treatment of murine lupus with cDNA encoding IFN-γR/Fc

Journal of Clinical Investigation

Volumn 106, Issue 2, 2000, Pages 207-215

  Lawson, Brian R ^a   Prud'homme, Gerald J ^b   Chang, Yigang ^b   Gardner, Humphrey A ^a   Kuan, Jason ^a   Kono, Dwight H ^a   Theofilopoulos, Argyrios N ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOIMMUNE DISEASE; CLINICAL FEATURE; DISEASE COURSE; DRUG EFFICACY; IMMUNE RESPONSE; LUPUS VULGARIS; MOUSE; NONHUMAN; PRIORITY JOURNAL;

EID: 0033942181     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI10167     Document Type: Article

References (50)

1. Boumpas, D.T., et al. 1995. Systemic lupus erythematosus: emerging concepts. Part 2: dermatologic and joint disease, the antiphospholipid antibody syndrome, pregnancy and hormonal therapy, morbidity and mortality, and parhogenesis. Ann. Int. Med. 123:42-53.
2. Theofilopoulos, A.N., and Kono, D.H. 1999. The genes of systemic autoimmunity. Proc. Assoc. Am. Physicians. 111:228-240.
3. Kaliyaperumal, A., Michaels, M.A., and Datta, S. 1999. Antigen-specific therapy of murine lupus nephritis using nucleosomal peptides: tolerance spreading impairs pathogenic function of autoimmune T and B cells. J. Immunol. 162:5775-5783.
4. Wofsy, D. 1993. Treatment of murine lupus with anti-CD4 monoclonal Antibodies. Immunol. Ser. 59:221-236.
5. Mohan, C., Shi, Y., Laman, J.D., and Datta, S.K. 1995. Interaction between CD40 and its ligand gp39 in the development of murine lupus nephritis. J. Immunol. 154:1470-1460.
6. Finck, B.K., Linsley, P.S., and Wofsy, D. 1994. Treatment of murine lupus with CTLA4Ig. Science 265:1225-1227.
7. Theofilopoulos, A.N., and Lawson, B.R. 1999. Tumour necrosis factor and other cytokines in murine lupus. Ann. Rheum. Dis. 58:149-155.
8. Kelley, V.R., and Wuthrich, R.P. 1999. Cytokines in the pathogenesis of systemic lupus erythematosus. Semin. Nephrol. 19:57-66.
9. Jacob, C.O., Van der Meide, P.H., and McDevitt, H.O. 1987. In vivo treatment of (NZB×NZW)F1 lupus-like nephritis with monoclonal antibody to gamma interferon. J. Exp. Med. 166:798-803.
10. Balomenos, D., Rumold, R., and Theofilopoulos, A.N. 1998. Interferon-gamma is required for lupus-like disease and lymphoaccumulation in MRL-lpr mice. J. Clin. Invest. 101:364-371.
11. Peng, S.L., Moslehi, J., and Craft, J. 1997. Roles of interferon-gamma and interleukin-4 in murine lupus. J. Clin. Invest. 99:1936-1946.
12. Haas, C., Ryffel, B., and LeHir, M. 1998. IFN-gamma receptor deletion prevents autoantibody production and glomerulonephritis in lupusprone (NZB×NZW)F1 mice. J. Immunol 160:3713-3718.
13. Haas, C., Ryffel, B., and LeHir, M. 1997. IFN-gamma is essential for the development of autoimmune glomerulonephritis in MRL/lpr mice. J. Immunol. 158:5485-5491.
14. lpi mice. J. Immunol. 161:494 503.
15. Piccirillo, C.A., and Prud'hommie, G.J. 1999. Prevention of experimental allergic encephalomyelins by intramuscular gene transfer with cyrokine-encoding plasmid vectors. Hum. Gene Ther. 10:1915-1922.
16. Prud'homme, G.J., Kono, D.H., and Theofilopoulos, A.N. 1995. Quantitative polymerase chain reaction analysis reveals marked overexpression of interleukin-1β, interleukin-10, and interferon-gamma mRNA in the lymph nodes of lupus-prone mice. Mol. Immunol. 32:495-503.
17. Hartikka, J., et al. 1996. An improved plasmic DNA expression vector for direct injection into skeletal muscle. Hum. Gene. Ther. 20:1205-1207.
18. Aihara, H., and Miyazaki, J.-I. 1998. Gene transfer into muscle by electroporarion in vivo. Nat. Biotechnol. 16:867-870.
19. Jung, T., Schauer, U., Heusser, C., Neumann, C., and Rieger, C. 1993. Detection of intracellular cytokines by flow cytometry. J. Immunol. Methods. 159:197-207.
20. Theofilopoulos, A.N., and Dixon, F.J. 1985. Marine models of systemic lupus erythematosus. Aav. Immunol. 37:269-390.
21. Nicoletti, F., et al. 1992. In vivo treatment with a monoclonal antibody to interferon-gamma neither affects the survival nor the incidence of lupus-nephritis in the MRL/lpr-lpr mouse. Immunopharmacology. 24:11-16
22. Ozmen, L., et al. 1995. Experimental therapy of systemic lupus erythematosus: the treatment of NZB/W mice with mouse soluble interferongamma receptor inhibits the onset of glomerulonephritis. Eur. J. Immunol. 25:6-12.
23. Raz, K., et al. 1993. Systimic immunological effects of cytokine genes injected into skeletal muscle. Proc. Natl. Acad. Sci. USA. 90:4523-4527.
24. Raz, E., et al. 1995. Modulation of disease activity in murine systemic lupus erythematosus by cyrokine gene delivery. Lupus. 4:286-292.
25. Ozmen, L., et al. 1993. Mouse soluble IFN-gamma receptor as IFN-gamma inhibitor. J Immunol. 150:2698-2705.
26. Kurschner, C., Ozmen, L. Garotta, G., and Dembic, Z 1992. IFN-gamma receptor-Ig fusion proteins. Hair-life, immunogenicity, and in vivo activity. J. Immunol. 149:4096-4100.
27. Kurschner, C., Garotta, G., and Dembic, Z. 1992. Construction, purification, and characterization of new interferon gamma (IFN gamma) inhibitor proteins. Three IFN gamma receptor-immunoglobulin hybrid molecules. J. Biol. Chem. 267:9354-9360.
28. Muramatsu, T., Nakjamura, A., and Park, H.-M. 1998. In vivo electroporation: a powerful and convenient means of nonviral gene transfer to tissues of living animals. Im. J. Mol. Med. 1:55-62.
29. Rois, M.-P., et al. 1998. In vivo electrically mediated protein and gene transfer in murine melanoma. Nat. Biotechnol. 16:168-171.
30. Horron, H.M, et al. 1999. A gene therapy for cancer using intramuscular injection of plasmid DNA encoding interferon-alpha. Proc. Natl. Acad. Sci. USA. 96:1553-1558.
31. Mir, L.M., et al. 1999. High-efficiency gene transfer into skeletal muscle mediated by electric pulses. Proc. Natl. Acad. Sci. USA. 96:4262-4267.
32. Takahashi, S., et al. 1996. Imbalance rewards Th1 predominance is associated with acceleration of lupus-like autoimmune syndrome in MRL mice. J. Clin. Invest. 97:1597-1558.
33. Kalled, S.L., Cutler, A.H , Darta, S.K., and Thomas, D.W. 1998. Anti-CD40 ligand antibody treatment of SNF1 mice with established nephritis: preservation of kidney function. J. Immunol. 160:2158-2165.
34. Daikh, D.I., Finck, H.K., Linsley, P.S., Hollenbaugh, D., and Wofsy, D. 1997. Long-term inhibition of murine lupus by brief simultaneous blockade of the B7/CD23 and CD40/gp39 costimulation pathways. J. Immunol. 159:3104-3108
35. Kawai, T., Andrews, H., Colvin, R.B. Sachs, D.H., and Cosimi, A.B. 2000. Thromboembolic complications after treatment with monoclonal antibody against CD40 ligand. Nat. Med. 6:114.
36. Boehm, U., Klamp, T., Groot, M., and Howard, J.C. 1997. Cellular responses to interferon-gimma. Anna. Rev. Immunol 15:749-795.
37. Kofler, R., Schreiber, R.D., Dixon, F.J., and Theofilopoulos, A.N. 1984. Macrophage 1-A/I-E expression and macrophage-stimulating lymphokines in murine lupin. Cell Immunol 87:92-100.
38. Kelley, V.H., and Roths, J.B. 1982. Increase in macrophage Ia expression in autoimmune mice: role of the lpr gene. J. Immunol. 129:923-925.
39. Wuthrich, R. P., et al. 1997. Enhanced MHC class II expression in renal proximal tubules precedes loss of renal function in MRL/lpr mice with lupus nephritis. Am J. Pathol. 134:45-51.
40. Wuthrich, R.P., et al. 1990. MHC class II, antigen presentation and rumor necrosis factor in renal tubular epithelial cells Kidney Int. 37:783-792.
41. Wuthrich, R.P., Jevnikar, A.M., Takei, F., Glimoner, L.H., and Kelley, V.E. 1990. Intercellular adhesion molecule-1 (ICAM-1) expression is upregulated in autoimmune murine lupus nephritis. Am. J. Pathol 136:441-450.
42. lpi mice. J. Exp. Med. 190:1813-1824.
43. Bullard, D.C., et al. 1997. Intercellular adhesion moloecule-1 deficiency protects MRL/MpJ-Fas (lpr) mice from early lethality. J. Immunol. 159:2058-2067.
44. Mathisen, P.M., and Tuohy, V.K. 1998. Gene therapy in the treatment of autoimmune disease. Immunol Today. 19:103-105.
45. Evans, C.H., Whalen, J.D., Evans, C.H., Ghivizzani, S.C., and Robbins, P.D. 1998. Gene therapy in autoimmune diseases. Ann. Rheum. Dis 57:125-127.
46. Mulligan, R.C. 1993. The basic science of gene therapy. Science. 260:926-931.
47. La Cava, A., et al. 2000. Cell-mediated DNA transport between distant inflammatory sites following intradermal DNA immunization in the presence of adjuvant. J. Immunol. 164:1340-1345.
48. Balasa, B., et al. 1997. Interferon gamma (IFN-gamma) is necessary for the genesis of acetylcholine receptor-induced clinical experimental autoimmune myasthema gravis in mice. J Exp. Med. 186:385-391
49. Zhang, G.-X., et al. 1999, Mice with IFN-γ receptor deficiency are less susceptible to experimental autoimmune myasthenia gravis. J. Immunol. 162:3775-3781.
50. Nicoletti, T., et al. 1996. The effects of a nonimmunogenic form of marine soluble inrerferon-γ receptor on the development of autoimmune diabetes in the NOD mouse. Endocrinology. 137:5567-5575.